

WEIGHT LOSS MEDICATION

(06/26/2024)

I. CODE OF FEDERAL REGULATIONS - 67.113(c); 67.213(c); & 67.313(c)

II. MEDICAL HISTORY: ITEM 48. General Systemic

The applicant must report frequency and duration of symptoms, any incapacitation by the condition, treatment, and side effects. If the applicant has diabetes, see that page.

III. AEROMEDICAL DECISION CONSIDERATIONS: See Item 48. General Systemic

IV. PROTOCOL: See either the [Prediabetes](#) or [Weight Loss Management](#) disposition tables.

V. PHARMACEUTICAL CONSIDERATIONS: Pilots exhibiting symptoms which may interfere with flight duties, regardless of the treatment used, must not fly in accordance with 61.53. The AME must notate the evaluation data in Block 60.

DIABETIC MEDICATIONS USED FOR WEIGHT LOSS*:

- A1C must be 6.4 or less with no diagnosis of diabetes AND
- No history of hypoglycemia requiring intervention

See [Weight Loss Management or Prediabetes Status Report](#).

If used for DIABETES, see www.faa.gov/go/diabetic

| ACCEPTABLE Weight Loss Medications When certification criteria are met. | |
|--|---|
| Medication Drug Class | Initial observation |
| <input type="checkbox"/> Lipase inhibitors – e.g., orlistat [Alli; Xenical]) - OTC | 48 hours |
| Treated with a single diabetic medication component: <ul style="list-style-type: none"> <input type="checkbox"/> metformin <input type="checkbox"/> GLP-1 agonist <ul style="list-style-type: none"> • liraglutide • semaglutide • tirzepatide (GIP + GLP-1 Agonist) <input type="checkbox"/> Combination of the following: <ul style="list-style-type: none"> • orlistat + metformin • orlistat + GLP-1 agonist | 2 weeks after starting for weight loss. 72-hour observation with each dosage change. GLP-1 Agonist medications: No history or evidence of substance use disorder, psychosis/psychotic symptoms, suicidal ideation, or self-destructive ideations at any time . See either the Prediabetes or Weight Loss Management disposition tables. |
| CONDITIONALLY ACCEPTABLE Weight Loss Medications (Requires SI) | |
| Medication Drug Class | Initial observation |
| Combination of two diabetic medications (2 components) e.g., metformin + GLP-1 agonist | See Acceptable Combinations of Diabetes Medications |
| UNACCEPTABLE Weight Loss Medications Use prohibited as a single agent or in any combination product. | |
| <input checked="" type="checkbox"/> Sympathomimetic (such as phentermine) <ul style="list-style-type: none"> • benzphetamine (Regimex) • diethylpropion (Tenuate, Tempanil) • phendimetrazine (Bontril) • phentermine (Adipex, Fastin) • phentermine + topiramate (Qsymia) | bupropion + naltrexone (Contrave) citric acid + cellulose (Plenity) Serotonin 5HT-2 Receptor Agonist <ul style="list-style-type: none"> • lorcaserin (Belviq) • fenfluramine hydrochloride (Pondimin) |